Abstract
Purpose
A disintegrin and metalloprotease with motif 5(ADAMTS5) has been involved in colorectal cancer (CRC) with hypermethylation in the promoter. However, its role in CRC remains unclear. The aim of this study was to explore the clinical significance and biological effect of ADAMTS5 on colorectal carcinogenesis. Through MSP, qRT-PCR, WB and IHC analysis, followed by a variety of in vitro assays, we report the function of ADAMTS5 in CRC. ADAMTS5 was markedly hypermethylaed and downregulated in tumor tissues compared with non-tumor tissues (p < 0.001). Negative expression of ADAMTS5 was much more common in tumor tissues than that in normal tissues (p < 0.001) and correlated with histologic types (p = 0.002), poor OS (p = 0.029) and DFS (p = 0.018). In vitro assay revealed that overexpression of ADAMTS5 inhibited the capabilities of migration and invasion of CRC cells, and no effect on cell growth, cell cycle and apoptosis. ADAMTS5 is hypermethylated and inhibits cancer cells invasion and migration in colorectal cancer, and correlates with OS and DFS, indicating that ADAMTS5 might be a useful biomarker in colorectal cancer therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Apte SS (2009) A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms. J Biol Chem 284:31493–31497. https://doi.org/10.1074/jbc.R109.052340
Choi GCG et al (2014) The Metalloprotease ADAMTS8 Displays Antitumor Properties through Antagonizing EGFR-MEK-ERK Signaling and Is Silenced in Carcinomas by CpG Methylation. Mol Cancer Res 12:228–238. https://doi.org/10.1158/1541-7786.MCR-13-0195
Cross NA, Chandrasekharan S, Jokonya N, Fowles A, Hamdy FC, Buttle DJ, Eaton CL (2005) The expression and regulation of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbeta1 in prostate cells: relevance to the accumulation of versican. Prostate 63:269–275. https://doi.org/10.1002/pros.20182
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917. https://doi.org/10.1002/ijc.25516
Gu J et al (2016) Overexpression of ADAMTS5 can regulate the migration and invasion of non-small cell lung. Cancer Tumor Biol 37:8681–8689. https://doi.org/10.1007/s13277-015-4573-x
Held-Feindt J, Paredes EB, Blomer U, Seidenbecher C, Stark AM, Mehdorn HM, Mentlein R (2006) Matrix-degrading proteases ADAMTS4 and ADAMTS5 (disintegrins and metalloproteinases with thrombospondin motifs 4 and 5) are expressed in human glioblastomas. Int J Cancer 118:55–61. https://doi.org/10.1002/ijc.21258
Kim YH et al (2011) Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations. Ann Surg Oncol 18:2338–2347. https://doi.org/10.1245/s10434-011-1573-y
Kintakas C, McCulloch DR (2011) Emerging roles for ADAMTS5 during development and disease. Matrix Biol J Int Soc Matrix Biol 30:311–317. https://doi.org/10.1016/j.matbio.2011.05.004
Koo BH, Hurskainen T, Mielke K, Aung PP, Casey G, Autio-Harmainen H, Apte SS (2007) ADAMTSL3/punctin-2, a gene frequently mutated in colorectal tumors, is widely expressed in normal and malignant epithelial cells, vascular endothelial cells and other cell types, and its mRNA is reduced in colon cancer International. J Cancer 121:1710–1716. https://doi.org/10.1002/ijc.22882
Kumar S, Sharghi-Namini S, Rao N, Ge RW (2012) ADAMTS5 functions as an anti-angiogenic and anti-tumorigenic protein independent of its proteoglycanase activity American. J Pathol 181:1056–1068. https://doi.org/10.1016/j.ajpath.2012.05.022
Li Z et al (2010) High-resolution melting analysis of ADAMTS18 methylation levels in gastric, colorectal and pancreatic cancers. Med Oncol 27:998–1004. https://doi.org/10.1007/s12032-009-9323-8
Li C et al (2015) Lost expression of ADAMTS5 protein associates with progression and poor prognosis of hepatocellular carcinoma. Drug Des Dev Therapy 9:1773–1783. https://doi.org/10.2147/DDDT.S77069
Lima MA et al (2016) Prognostic Value of ADAMTS Proteases and Their Substrates in Epithelial. Ovarian Cancer Pathobiol 83:316–326. https://doi.org/10.1159/000446244
Lind GE, Kleivi K, Meling GI, Teixeira MR, Thiis-Evensen E, Rognum TO, Lothe RA (2006) ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. Cell Oncol 28:259–272
Moncada-Pazos A et al (2009) The ADAMTS12 metalloprotease gene is epigenetically silenced in tumor cells and transcriptionally activated in the stroma during progression of colon cancer. J Cell Sci 122:2906–2913. https://doi.org/10.1242/jcs.050468
Porter S et al (2004) Dysregulated expression of adamalysin-thrombospondin genes in human breast carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res 10:2429–2440
Stanton H et al (2005) ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 434:648–652. https://doi.org/10.1038/nature03417
Tiscornia G, Singer O, Verma IM (2006) Production and purification of lentiviral vectors. Nat Protocols 1:241–245. https://doi.org/10.1038/nprot.2006.37
Viloria CG et al (2009) Genetic inactivation of ADAMTS15 metalloprotease in human colorectal cancer. Cancer Res 69:4926–4934. https://doi.org/10.1158/0008-5472.CAN-08-4155
Yang ZL et al. (2014) Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer BMC cancer 14 Artn. 568. https://doi.org/10.1186/1471-2407-14-568
Yang Z et al (2015) Epigenetic inactivation and tumor-suppressor behavior of NGFR in human colorectal cancer. MCR 13:107–119. https://doi.org/10.1158/1541-7786.MCR-13-0247
Zhang C et al (2010) High-resolution melting analysis of ADAMTS9 methylation levels in gastric, colorectal, and pancreatic cancers. Cancer Genet Cytogenet 196:38–44. https://doi.org/10.1016/j.cancergencyto.2009.08.016
Author information
Authors and Affiliations
Contributions
There were no sources of editorial support in the preparation of this manuscript. All authors have read the journal’s authorship agreement and have reviewed and approved the manuscript.
Corresponding author
Ethics declarations
Funding
This study was funded by the Science and Technology Planning Project of Guangdong Province (No.2013B021800052; No.2014A020212706) and National Natural Science Foundation of Guangdong (No. 2015A030313008), China.
Conflict of interest
All authors have read the journal’s policy on the disclosure of potential conflicts of interest and have none to declare.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review boards of Sun Yat-Sen University (Guangzhou, China) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Li, J., Liao, Y., Huang, J. et al. Epigenetic silencing of ADAMTS5 is associated with increased invasiveness and poor survival in patients with colorectal cancer. J Cancer Res Clin Oncol 144, 215–227 (2018). https://doi.org/10.1007/s00432-017-2545-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-017-2545-9